(SLDB) Solid Biosciences Inc. Business Model Canvas Research

Solid Biosciences Inc. relies on research partners to advance its dual gene expression and capsid design work, since outside scientists can speed discovery, improve vector optimization, and test new ideas faster. This matters in AAV therapy, where even small capsid gains can change delivery and expression.

External collaboration also helps validate therapeutic concepts before heavier spend; Solid Biosciences Inc. ended 2025 with a pipeline built around multiple neuromuscular and gene therapy programs, so partner input can de-risk each step. One clear result: faster learning with lower scientific blind spots.

• Speeds vector and capsid optimization
• Validates new gene therapy concepts
• Shares scientific risk and know-how

Patient advocacy and rare-disease groups are key for Solid Biosciences Inc. because Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 male births and roughly 15,000 males in the U.S. They help raise trial awareness, explain unmet need, and support recruitment and retention, while also shaping real-world priorities around mobility, steroid burden, and caregiver impact.

• Boosts trial awareness and trust
• Supports education and recruitment
• Surfaces unmet-need priorities

Solid Biosciences Inc. is building new capsids to improve delivery, since capsid choice can shift tissue targeting, potency, and immune response; that work supports both current and future gene therapy programs. In 2025, the company kept R&D as a core spend, backing this platform work across its pipeline.

• Better delivery can raise potency

• Capsid choice can reduce immune risk

• Supports present and future programs

Solid Biosciences Inc. relies on regulatory, quality, and translational operations to keep its clinical-stage gene therapy programs compliant, inspection-ready, and tied to human data. These teams manage safety reporting, GMP manufacturing readiness, and trial controls, which is critical in a field where one missed filing or batch issue can slow later-stage progress.

• Regulatory filings support trial continuity
• Quality systems protect manufacturing readiness
• Translational studies link lab to clinic

Capsid engineering know-how is a core scientific asset for Solid Biosciences Inc. because AAV vectors carry only about 4.7 kb of DNA and the capsid is roughly 25 nm wide, so small design changes can lift delivery efficiency and tissue targeting. That know-how helps turn gene therapy from a lab tool into a repeatable product.

• Improves AAV delivery
• Drives tissue selectivity
• Supports IP value

In practice, this resource can shape dose needs, safety, and program economics, which matters when every vector copy and every patient dose has real cost.

Solid Biosciences Inc. is based in Cambridge, Massachusetts, where its headquarters houses research, development, and corporate teams. Being in the Boston life-science hub gives Solid access to deep talent, lab partners, and a dense biotech network, which matters for a company still scaling clinical and platform work.

• Cambridge HQ anchors R&D and corporate functions
• Boston biotech cluster supports hiring
• Location aids collaboration and recruiting

Solid Biosciences Inc.’s dual-gene expression platform can pack more than one therapeutic gene into one AAV vector, which matters because AAV payload space is only about 4.7 kb. That lets one dose potentially address a broader disease path, and it is a clear platform differentiator versus single-gene designs.

• Two genes, one vector
• Fits AAV size limits
• Broader one-dose reach
• Differentiated platform value

Solid Biosciences Inc. builds value with one clinical candidate, one next-gen candidate, and platform tech, so the story is bigger than one asset. That mix supports partnering and keeps the rare-disease pipeline expanding; as of 2025, the model is designed to spread risk across multiple shots on goal.

• Clinical plus next-gen assets
• Platform tech broadens value
• Supports partnerships and scale

Solid Biosciences Inc.’s Ultragenyx alliance needs tight partner account management: one active collaboration still depends on joint planning, data sharing, and commercialization talks to keep execution on track. That matters because Solid Biosciences Inc. had to manage a small partner base in 2025, so each governance cycle can shape future market access and launch readiness.

• Joint steering keeps work aligned
• Shared data speeds decisions
• Commercial talks shape market access

Scientific transparency is central to Solid Biosciences Inc.’s trust with clinicians and investors: biotech credibility rises when clinical, preclinical, and regulatory updates are shared in SEC filings, conference talks, and peer-reviewed forums. In 2025, this matters even more as the Company advances DMD programs like SGT-003, where clear data disclosure helps physicians judge benefit-risk and supports investor confidence.

• Share clinical updates fast
• Publish preclinical data clearly
• Back claims with filings
• Build doctor and investor trust

Solid Biosciences Inc.’s Ultragenyx partner network gives a path to future development and commercialization beyond its own sales reach. That channel matters most in later-stage market access, where a larger rare-disease partner can help move a therapy from clinic to payer and patient faster.

• Extends reach beyond Solid’s internal footprint
• Supports later-stage market access
• Improves commercialization readiness

Patient advocacy groups and neuromuscular specialist referrals are a key channel for Solid Biosciences Inc., because Duchenne muscular dystrophy is rare, affecting about 1 in 3,500 to 5,000 male births. These networks help families find trial sites fast, which raises awareness and cuts recruitment friction in a small, concentrated patient pool.

In 2025, this matters even more as Solid Biosciences Inc. relies on high-touch enrollment for gene-therapy studies, where each eligible patient can affect timelines and spend.

• Speeds trial awareness
• Improves referral quality
• Lowers recruitment cost

Hospitals and gene therapy centers are Solid Biosciences Inc.’s key delivery partners: they handle one-time IV infusions, patient monitoring, and follow-up after treatment. Because these therapies need specialized staff and safety checks, access to a limited number of certified centers drives adoption and repeat referrals.

• Infusion, monitoring, follow-up
• Specialized centers, not routine clinics
• Key operational customers and partners

Payers and pharmaceutical partners are key for Solid Biosciences Inc. because reimbursement drives uptake and partners help fund development and launch. In 2025, the company was still pre-commercial, so access will depend on payer coverage and partner-backed execution to turn its AAV programs into revenue.

• Health plans decide reimbursement.
• Biotech partners can fund launch.
• Both shape market access speed.

Solid Biosciences Inc.'s general and administrative overhead covers corporate, legal, finance, HR, audit, and SEC reporting work that keeps the public company running outside the lab. For a public biotech, this spend is recurring and can rise with governance, compliance, and stock-based pay tied to hiring and retention.

• Corporate and legal support
• SEC reporting and audit costs
• Finance and HR operations
• Public-company governance burden

Solid Biosciences Inc. carries recurring regulatory, legal, and IP costs because each clinical program needs FDA submissions, safety reporting, and ongoing compliance. These costs also support patent filing and maintenance, which help protect the pipeline and keep the Duchenne-focused gene therapy platform defensible.

For a clinical-stage biotech, this bucket is not optional: it scales with trial count, monitoring load, and patent life. It also sits beside R&D spend, so tighter program activity can lower cash burn while still protecting core assets.

• Regulatory filings and safety reports
• Clinical compliance and legal review
• Patent filings and maintenance fees
• Pipeline protection and exclusivity support

Solid Biosciences Inc. can earn royalties if a partner commercializes a licensed therapy, so revenue can come in without running manufacturing or sales. This model is common in biotech; Solid Biosciences is still largely pre-commercial, so royalty income would likely matter only after downstream approvals.

• Partner-led launches can pay royalties
• No direct manufacturing burden
• Fits biotech licensing economics

Research grants can fund Solid Biosciences Inc.'s early platform work and preclinical steps without adding shares. For rare-disease biotech, that matters because clinical-stage firms often burn cash before product revenue arrives, so non-dilutive funding helps bridge long R&D cycles and reduce dilution.

• Supports early research
• Limits equity dilution
• Fits rare-disease funding needs